Investments and Fair Value Measurements - Ampreloxetine Funding (Details) - USD ($) $ in Millions	9 Months Ended
Sep. 30, 2024	Jul. 31, 2022
Ampreloxetine Royalty Rights
Development and Collaboration Agreement
Milestone payments		$ 15.0
Carrying amount of the liability		25.0
Percent of effective interest rate	8.30%
Ampreloxetine Funding
Development and Collaboration Agreement
Consideration Receivable at closing		$ 25.0

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration